Patient Name : Miss.
DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 12:19PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 01:51PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method
COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA
HAEMOGLOBIN 12.3 g/dL 12-15 Spectrophotometer
PCV 37.20 % 36-46 Electronic pulse &
Calculation
RBC COUNT 4.52 Million/cu.mm 3.8-4.8 Electrical Impedence
MCV 82 fL 83-101 Calculated
MCH 27.3 pg 27-32 Calculated
MCHC 33.2 g/dL 31.5-34.5 Calculated
R.D.W 14.1 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 8,100 cells/cu.mm 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 67 % 40-80 Electrical Impedance
LYMPHOCYTES 28 % 20-40 Electrical Impedance
EOSINOPHILS 02 % 1-6 Electrical Impedance
MONOCYTES 03 % 2-10 Electrical Impedance
BASOPHILS 00 % <1-2 Electrical Impedance
CORRECTED TLC 8,100 Cells/cu.mm Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 5427 Cells/cu.mm 2000-7000 Calculated
LYMPHOCYTES 2268 Cells/cu.mm 1000-3000 Calculated
EOSINOPHILS 162 Cells/cu.mm 20-500 Calculated
MONOCYTES 243 Cells/cu.mm 200-1000 Calculated
Neutrophil lymphocyte ratio (NLR) 2.39 0.78- 3.53 Calculated
PLATELET COUNT 394000 cells/cu.mm 150000-410000 Electrical impedence
MPV 7.8 Fl 8.1-13.9 Calculated
Page 1 of 9
SIN No:BED250081792
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 12:00PM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 04:48PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 07:00PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
HOMA2 IR (INSULIN RESISTANCE INDEX)
INSULIN (FASTING) 16.3 µIU/mL 1.9-23 CLIA
FASTING GLUCOSE 82.8 mg/dL 70-100 HEXOKINASE
BETA CELL FUNCTION (%B) 190.2 % >87.12 CALCULATED
INSULIN SENSITIVITY (%S) 49.2 % >53.9 CALCULATED
HOMA2 IR INDEX 2.03 <1.69 CALCULATED
QUICKI 0.32 >0.45 CALCULATED
Comment:
HOMA2 IR
INTERPRETATION QUICKI INTERPRETATION
INDEX
<1.69 Normal Insulin Resistance >0.45 Normal, non- diabetic
1.69-2.72 Moderate Insulin Resistance 0.3 - 0.45 Insulin resistance likely
>2.72 Severe Insulin Resistance <0.30 Diabetes diagnosis likely
HOMA2-IR (Homeostatic Model Assessment for Insulin Resistance):
a) HOMA2 is the updated HOMA model where HOMA2 calculator (version 2.2) is used to calculate HOMA2 IR index, beta cell function (%B) and insulin sensitivity (%S)
from fasting glucose and insulin concentrations.
b) HOMA2 IR index is used to measure severity of insulin resistance, though normal insulin resistance varies depending on the population It is most useful for
epidemiologic, population-based, and other group level assessments.
c) HOMA2-IR index is an alternative for estimating insulin resistance (IR), has been examined in multiple studies. Results show reasonable correlation between HOMA2-
IR and ‘clamp’ measurement, the gold standard.
d) HOMA2-IR index should not be used in patients on insulin, and studies have shown its limited accuracy in those with impaired glucose tolerance, normal BMI and
elderly.
QUICKI (Quantitative Insulin Sensitivity Check Index):
a) QUICKI is an index used to assess insulin resistance, just like HOMA2-IR from fasting glucose and insulin concentrations.
b) The smaller the QUICKI index is, the larger the probability there is a carbohydrate metabolism disorder.
c) QUICKI has been shown to be a useful index of insulin sensitivity in various populations, including those with hypertension and type 2 diabetes.
Reference:
https://www.rdm.ox.ac.uk/about/our-facilities-and-units/DTU/software/homa
https://www.omnicalculator.com/health/quicki
Page 2 of 9
SIN No:SPL25035841
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 12:00PM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 04:48PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 06:48PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM
TRI-IODOTHYRONINE (T3, TOTAL) 221.07 ng/dL 87-178 CLIA
THYROXINE (T4, TOTAL) 9.37 µg/dL 5.48-14.28 CLIA
TSH (Ultrasensitive/4thGen) 2.749 µIU/mL 0.38-5.33 CLIA
Comment:
For pregnant females Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0
1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) & its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit
production of TSH.
2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or
hyperthyroidism respectively.
3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is
free and biologically active. Isolated low T3 is often noticed in elderly
4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.
TSH T3 T4 FT4 Possible Suggested Conditions correlating with pattern
High Low Low Low Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High N N N Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low Low Low Low Secondary and Tertiary Hypothyroidism
Low High High High Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low N N N Subclinical Hyperthyroidism
Low Low Low Low Central Hypothyroidism, Treatment with Hyperthyroidism
Low N High High Thyroiditis, Interfering Antibodies
N/Low High N N T3 Thyrotoxicosis, Non thyroidal causes
High High High High Pituitary Adenoma; TSHoma/Thyrotropinoma
Page 3 of 9
SIN No:SPL25035841
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 04:48PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 06:48PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
FOLLICLE STIMULATING HORMONE 4.03 mlU/mL CLIA
(FSH) , SERUM
Comment:
REFERENCE GROUP REFERENCE RANGE IN mIU/mL
FEMALES
* FOLLICULAR PHASE 3.03 - 8.08
* MID CYCLE PEAK 2.56 - 16.69
* LUTEAL PHASE 1.38 - 5.47
* POSTMENOPAUSAL FEMALE 26.72 - 133.41
MALES 0.95 - 11.95
Abnormal FSH levels are interpreted with increased or decreased levels of other fertility hormones such as LH, estrogens,
progesterone, and testosterone.
Increased FSH levels are associated with menopause and primary ovarian hypofunction in females and primary hypogonadism in
males.Decreased FSH levels are associated with primary ovarian hyperfunction in females and primary hypergonadism in males.
Normal or decreased FSH levels are associated with polycystic ovary disease in females.
Page 4 of 9
SIN No:SR04948936
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 04:48PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 06:48PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
LH:LUTEINIZING HORMONE , SERUM 8.36 mlU/mL CLIA
Comment:
REFERENCE GROUP REFERENCE RANGE IN mIU/mL
FEMALES
FOLLICULAR PHASE 1.80 – 11.78
MID CYCLE PEAK 7.59 – 89.08
LUTEAL PHASE 0.56 - 14.0
POSTMENOPAUSAL FEMALE NOT ON HRT 5.16 - 61.99
MALES 0.57 - 12.07
Abnormal LH levels are interpreted with increased or decreased levels of other fertility hormones such as FSH, estrogens,
progesterone, and testosterone.
Increased LH levels are associated primary ovarian hypogonadism and gonadotropin secreting pituitary tumors. Decreased LH
levels are associated with Hypothalamic GnRH deficiency, Pituitary LH deficiency, Ectopic steroid hormone production, GnRH
analog treatment.
Page 5 of 9
SIN No:SR04948936
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 04:48PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 06:13PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
VITAMIN D (25 - OH VITAMIN D) , 11.82 ng/mL 30 -100 CLIA
SERUM
Comment:
BIOLOGICAL REFERENCE RANGES
VITAMIN D STATUS VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY <10
INSUFFICIENCY 10 – 30
SUFFICIENCY 30 – 100
TOXICITY >100
The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is
the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency
can also cause osteomalacia, which frequently affects elderly patients.
Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of
which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as
well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.
Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D,
which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin
D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval
of greater than 30 ng/mL is a target value established by the Endocrine Society.
Decreased Levels:- Inadequate exposure to sunlight, Dietary deficiency, Vitamin D malabsorption, Severe Hepatocellular
disease., Drugs like Anticonvulsants, Nephrotic syndrome.
Increased levels:- Vitamin D intoxication.
Page 6 of 9
SIN No:SR04948936
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 04:48PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 06:13PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
VITAMIN B12 , SERUM 204 pg/mL 120-914 CLIA
Comment:
Population based data reflecting exact scenario of vitamin B12 levels in Indian population is still evolving, however, different studies
reporting a deficiency in adults, pregnant women and children ranging from 16% to 77% with average of about 47%. This high
incidence is attributed to vegetarian food habits of large majority of Indian population.
Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss
of proprioception, poor coordination, and affective behavioral changes. A significant increase in RBC MCV may be an important
indicator of vitamin B12 deficiency. B12 levels in the range of 150 to 190 pg/ml may not be associated with any clinical
manifestations, while B12 levels below 100 pg/ml are often associated with clinical symptoms. However, for an individual based on
other co-morbid conditions or other nutritional deficiency (especially folate) the manifestations can vary accordingly.
If clinical symptoms suggest deficiency, measurement of active vitamin B12, MMA and homocysteine should be considered as
further workup.
Page 7 of 9
SIN No:SR04948936
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 01:38PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 03:30PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF CLINICAL PATHOLOGY
Test Name Result Unit Bio. Ref. Interval Method
COMPLETE URINE EXAMINATION (CUE) , URINE
Physical Examination
COLOUR PALE YELLOW PALE YELLOW Visual
TRANSPARENCY CLEAR CLEAR Physical Measurement
pH 5.00 5-7.5 Double Indicator
SP. GRAVITY 1.025 1.002-1.030 Bromothymol Blue
BIOCHEMICAL EXAMINATION
URINE PROTEIN NEGATIVE NEGATIVE Protein Error Of
Indicator
GLUCOSE NEGATIVE NEGATIVE Glucose Oxidase
URINE BILIRUBIN NEGATIVE NEGATIVE Azo Coupling Reaction
URINE KETONES (RANDOM) NEGATIVE NEGATIVE Sodium Nitro Prusside
UROBILINOGEN Normal NORMAL Modifed Ehrlich
Reaction
NITRITE NEGATIVE NEGATIVE Diazotization
LEUCOCYTE ESTERASE NEGATIVE NEGATIVE Leucocyte Esterase
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY
Pus Cells 1-2 /hpf 0-5 Microscopy
EPITHELIAL CELLS 2-4 /hpf <10 Microscopy
RBC 0-1 /hpf 0-2 Microscopy
CASTS NIL 0-2 Hyaline Cast Microscopy
CRYSTALS ABSENT ABSENT Microscopy
OTHERS NIL Microscopy
Comment:
All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods.
Microscopy findings are reported as an average of 10 high power fields.
*** End Of Report ***
Result/s to Follow:
HBA1C (GLYCATED HEMOGLOBIN)
Page 8 of 9
SIN No:UR2466235
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 01:38PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 03:30PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
DEPARTMENT OF CLINICAL PATHOLOGY
Page 9 of 9
SIN No:UR2466235
Patient Name : Miss.DISHA PANDA Collected : 12/Sep/2025 11:59AM
Age/Gender : 20 Y 7 M 10 D/F Received : 12/Sep/2025 01:38PM
UHID/MR No : RSHI.0000076276 Reported : 12/Sep/2025 03:30PM
Visit ID : RSHIOPV341302 Status : Final Report
Ref Doctor : Dr.Dr. DEEPTI SOOD HANDA
TERMS AND CONDITIONS GOVERNING THIS REPORT
1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understand
reporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever
2. This is computer generated medical diagnostics report that has been validated by an Authorized Medical Practitioner/Doctor. The
report does not need physical signature.
3. Partial reproduction of this report is not valid and should not be resorted to draw any conclusion.
4. In the case you are not the intended recipient of this report. Please immediately return the same to the concerned issuing desk. Any
disclosure, copy or distribution of any contents of this report, is unlawful and is strictly prohibited.
5. Results delays may occur due to unforeseen circumstances such as non-availability of kits, equipment breakdown, natural calamities,
IT downtime, logistic delays or any other unavoidable event. For certain tests based on analyte stability, criticality of results and in the
interest of patient for having appropriate medical diagnosis, the same test may be outsourced to other accredited laboratory.
6. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of
particulars have been confirmed by the patient or his / her representative at the point of generation of said specimen
7. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
8. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies
9. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
10. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only
SIN No:UR2466235
